These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 35504814)

  • 41. Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality.
    Tsitoura E; Trachalaki A; Vasarmidi E; Mastrodemou S; Margaritopoulos GA; Kokosi M; Fanidis D; Galaris A; Aidinis V; Renzoni E; Tzanakis N; Wells AU; Antoniou KM
    Front Immunol; 2021; 12():645548. PubMed ID: 34867934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease activity of lung cancer at the time of acute exacerbation of interstitial lung disease during cytotoxic chemotherapy.
    Sekine A; Matama G; Hagiwara E; Tabata E; Ikeda S; Oda T; Okuda R; Kitamura H; Baba T; Satoh H; Misumi T; Komatsu S; Iwasawa T; Ogura T
    Thorac Cancer; 2022 Sep; 13(17):2443-2449. PubMed ID: 35840339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
    Araki K; Kinoshita R; Tomonobu N; Gohara Y; Tomida S; Takahashi Y; Senoo S; Taniguchi A; Itano J; Yamamoto KI; Murata H; Suzawa K; Shien K; Yamamoto H; Okazaki M; Sugimoto S; Ichimura K; Nishibori M; Miyahara N; Toyooka S; Sakaguchi M
    J Mol Med (Berl); 2021 Jan; 99(1):131-145. PubMed ID: 33169236
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
    Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
    Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Surgical Treatment of Lung Cancer Combined with Interstitial Lung Disease].
    Huang C; Ma C; Wu Q; Jiao P; Sun Y; Tian W; Yu H; Huang W; Wang Y; Tong H
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):343-350. PubMed ID: 32429636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.
    Kanaji N; Tadokoro A; Kita N; Murota M; Ishii T; Takagi T; Watanabe N; Tojo Y; Harada S; Hasui Y; Kadowaki N; Bandoh S
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1855-65. PubMed ID: 27350261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
    Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
    Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury.
    Smit PJ; Guo WA; Davidson BA; Mullan BA; Helinski JD; Knight PR
    J Surg Res; 2014 Sep; 191(1):214-23. PubMed ID: 24814199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
    Nakao S; Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Respir Med; 2020 Oct; 172():106131. PubMed ID: 32911136
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis].
    Kolek V; Vašáková M; Šterclová M; Cwiertka K; Vrána D; Kudláček A; Skřičková J; Pešek M; Petera J
    Klin Onkol; 2017; 30(4):303-306. PubMed ID: 28832178
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis.
    Moua T; Westerly BD; Dulohery MM; Daniels CE; Ryu JH; Lim KG
    Chest; 2016 May; 149(5):1205-14. PubMed ID: 26836940
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute exacerbation of idiopathic pulmonary fibrosis triggered by
    Suzuki A; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Mori Y; Kondoh Y
    Respir Med Case Rep; 2018; 23():103-106. PubMed ID: 29719792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
    Okuda R; Hagiwara E; Katano T; Ikeda S; Sekine A; Kitamura H; Baba T; Okudela K; Ohashi K; Ogura T
    Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):39-46. PubMed ID: 32476935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive biomarker analysis of patients with idiopathic pulmonary fibrosis and interstitial lung disease with healthy individuals.
    Balci A; Düz ME; Vurmaz A; Çilekar Ş; Kaya F
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5468-5479. PubMed ID: 37401283
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease.
    Ishikawa G; Acquah SO; Salvatore M; Padilla ML
    Respir Med; 2017 Jul; 128():78-84. PubMed ID: 28610674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases.
    Enomoto N; Naoi H; Mochizuka Y; Isayama T; Tanaka Y; Fukada A; Aono Y; Katsumata M; Yasui H; Mori K; Karayama M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
    BMC Pulm Med; 2022 Oct; 22(1):387. PubMed ID: 36289542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interstitial pneumonia with autoimmune features show better survival and less exacerbations compared to idiopathic pulmonary fibrosis.
    Lim JU; Gil BM; Kang HS; Oh J; Kim YH; Kwon SS
    BMC Pulm Med; 2019 Jul; 19(1):120. PubMed ID: 31272428
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.
    Enomoto N; Oyama Y; Enomoto Y; Yasui H; Karayama M; Kono M; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
    Chron Respir Dis; 2019; 16():1479972318809476. PubMed ID: 30380910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Interstitial Lung Disease-Gender-Age-Physiology Index Can Predict the Prognosis in Surgically Resected Patients with Interstitial Lung Disease and Concomitant Lung Cancer.
    Ueno F; Kitaguchi Y; Shiina T; Asaka S; Yasuo M; Wada Y; Kinjo T; Yoshizawa A; Hanaoka M
    Respiration; 2020; 99(1):9-18. PubMed ID: 31554007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.